Skip to main content
SpringerLink
Log in

The licensing gamble: raising the stakes

  • From the Analyst's Couch
  • Published:

From Nature Reviews Drug Discovery

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: In-licensing therapy area priorities for the 2002 top 20 big pharma companies.
Figure 2: Licensing activity for the top 20 pharma companies steadily increased in the decade 1988–1998 before beginning to flatten off as companies have begun to revise their licensing strategies.
Figure 3
Figure 4: Revenues of the top 20 pharma companies derived from in-licensed products and in-house developed products.

References

  1. Kalamas, J. & Pinkus, G. From the analyst's couch: the optimum time for drug licensing. Nature Rev. Drug Discov. 2, 691–692 (2003).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wood Mackenzie Limited, 5th Floor, Tower 42, 25 Old Broad Street, London, EC2N 1HN, UK

    James Featherstone & Siân Renfrey

Authors
  1. James Featherstone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Siân Renfrey
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Featherstone, J., Renfrey, S. The licensing gamble: raising the stakes. Nat Rev Drug Discov 3, 107–108 (2004). https://doi.org/10.1038/nrd1310

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd1310

  • Springer Nature Limited

This article is cited by

Search

Navigation